ARGX•benzinga•June 10, 2025 at 10:12 PM

argenx SE To Present Results From Phase 2 Studies Evaluating VYVGART In Sjogren's Disease And Idiopathic Inflammatory Myopathies At EULAR 2025; Co. Announces That The U.S FDA Has Granted Efgartigimod Fast Track Designation For The Treatment Of Primary Sj

No summary available.

Read the full article from the original source for complete details and context.

Article published on June 10, 2025 by benzinga